The new company will support drug discovery research. Credit: Diane Serik / Unsplash. Japanese firm Teijin has announced its basic agreement on a capital and business alliance with Axcelead to establish a drug discovery research joint venture (JV) company. The new company will mainly use Teijin Group’s core healthcare company, Teijin Pharma’s drug discovery research capabilities, facilities, personnel, technologies, and equipment. Its name, ownership ratio and other details are yet to be decided

Proprietary delivery platform, based on endogenous human proteins, offers the potential to enable genetic medicines across a broad range of modalities and therapeutic areas Founded by world-renowned scientist Feng Zhang, Ph.D., of the Broad Institute of MIT and Harvard, and joined by a distinguished set of industry leaders and company builders $193 million raised from leading life sciences investors ARCH Venture Partners, GV and Lux Capital Aera Therapeutics announced its launch today with a vis

First Patient in Florida Treated with Non-invasive Focused Ultrasound Technology Delray Medical Center is the first hospital in Florida to treat an Alzheimer's disease patient using non-invasive focused ultrasound technology as part of a groundbreaking study being conducted in collaboration with Florida Atlantic University's Institute for Human Health and Disease Intervention (I-Health). In the FDA-approved clinical trial, focused ultrasound technology is used to disrupt the blood-brain barrier

-COYA 301 is an immunomodulatory cytokine for subcutaneous administration, intended to enhance regulatory T cell (Treg) function in vivo to treat the systemic and neuro-inflammation underlying certain autoimmune and neurodegenerative diseases. -The original agreement provided Coya with global exclusive rights to develop and commercialize COYA 301 as a combination therapy across multiple therapeutic areas and disease conditions, and as a monotherapy for multiple neurodegenerative conditions. -The

AQILION AB ("Aqilion") today announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. Merck will make an upfront cash payment of EUR 10 million to Aqilion. In addition, Aqilion is eligible to receive potential development and commercialization milestones up to over EUR 950 million and tiered royalties on worldwide net sales. The collaborat

The collaboration integrates Google Cloud’s secure cloud data architecture and machine learning into the Asensus surgical robot platform. It further expands the capabilities of Asensus’ performance-guided surgery framework through its Intelligent Surgical Unit (ISU). Research Triangle Park, North Carolina–based Asensus designed its performance-guided surgery to enhance accuracy and efficiency. The company says its platform can help surgeons avoid complications and improve patient outcomes. The I

Photo courtesy of Insulet Mass.-based insulin-pump maker Insulet acquired assets related to Bigfoot Biomedical's pump-based automated insulin delivery (AID) technologies for $25 million. Insulet and Bigfoot offer two distinct forms of diabetes-management care: Insulet's Omnipod system that delivers insulin via a wearable, tubeless pump dubbed the Pod; and a remote controller called the Personal Diabetes Manager (PDM). Bigfoot's Unity provides injection support technologies that leverage smart pe

GE HealthCare has a vision for how it wants to shape the future of ultrasounds. The company wants ultrasound technology to be “used by nearly every clinician in nearly every situation in nearly every country around the world,” Karley Yoder, chief digital officer of GE HealthCare’s ultrasound division, said in an interview. Last week, GE HealthCare announced a deal that Yoder thinks will bring the company closer to achieving that vision. The firm unveiled its plan to acquire Caption Health, a com

近日，赛诺菲公布了2022年四季度和全年业绩，全球营收429.97亿欧元（约合453.6亿美元），同比增长13.87%，净利润68.33亿欧元，同比增长8.84%。其中处方药业务306.88亿欧元（323.76亿美元），同比增长13.8%，疫苗业务72.29亿欧元（76.27亿美元），同比增长14.3%，消耗品业务50.8亿欧元（53.59亿美元），同比增长13.7%。但考虑到欧元贬值，汇率转换后的总营收增长实际为7.0%，三大业务分别同比增长6.9%、6.3%和8.6%。处方药、疫苗和消耗品的销售成本分别为75.11亿欧元，41.01亿欧元和18.27亿欧元，毛利水平分别为77.7%，66.3%和65.3%，公司总体毛利水平为73.7%。处方药、疫苗和消耗品的研发投入强度分别为16.5%、12.9%和3.7%，公司整体研发投入67.06亿欧元，占总营收的15.6%。处方药、疫苗和消耗品的市场&管理费用分别占其销售额的19.7%，12.7%和29.1%，而公司整体水平为24.4%。处方药、疫苗和消耗品的税息前营业利润水平分别为36.0%，43.8%和35.6%。与去年同期相比，赛诺菲三

Abbott will gain an innovative, complementary solution in treating vascular disease through CSI's leading atherectomy system, which prepares vessels for angioplasty or stenting to restore blood flow CSI's offering will support Abbott's ability to provide better care for patients with peripheral and coronary artery disease ABBOTT PARK, Ill. and ST. PAUL, Minn., Feb. 8, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott